Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An update from Grand Pharmaceutical Group Limited ( (HK:0512) ) is now available.
Grand Pharmaceutical Group has entered into a product cooperation agreement with Pediatrix Therapeutics Technology (Shanghai) to secure exclusive commercialization rights for Neffy, the world’s first adrenaline nasal spray for emergency treatment of type I allergic reactions, in Mainland China and non-exclusive rights in Hong Kong. Led by its Beijing subsidiary, the group plans to localize production within 24 months of Chinese regulatory approval, positioning itself to address a growing incidence of severe allergic reactions and a significant treatment gap in China, where only injectable adrenaline is currently available and underused in emergencies. Neffy, already approved in the United States, European Union and Japan, offers a non-injectable, easy-to-use nasal spray format with a long shelf life, which could improve patient access, portability and adherence, and strengthen Grand Pharmaceutical’s role in emergency and pediatric care while leveraging Pediatrix’s expertise in pediatric drug innovation.
The most recent analyst rating on (HK:0512) stock is a Buy with a HK$10.00 price target. To see the full list of analyst forecasts on Grand Pharmaceutical Group Limited stock, see the HK:0512 Stock Forecast page.
More about Grand Pharmaceutical Group Limited
Grand Pharmaceutical Group Limited is a Bermuda-incorporated pharmaceutical company listed in Hong Kong, operating through subsidiaries such as Grand Pharma (Beijing) Co., Ltd. The group focuses on developing and commercializing innovative medicines and medical products in China and the broader Asia-Pacific region, with an emphasis on expanding its portfolio in high-need therapeutic areas through partnerships and localized production.
Average Trading Volume: 6,278,641
Technical Sentiment Signal: Buy
Current Market Cap: HK$29.07B
For a thorough assessment of 0512 stock, go to TipRanks’ Stock Analysis page.